Delivery Order SPE2DB25D3109-SPE2DB26FP4NQ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Kerendia 10 mg tablets (30-count packages) valued at $3,603.95. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract is scheduled for completion by September 29, 2025, with performance taking place at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,060.46 to AmerisourceBergen Drug Corp for Kerendia 20 mg tablets (30-count package) on August 25, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation represents a small-value pharmaceutical delivery under the company's larger federal contract portfolio. The place of performance is listed as Conshohocken, Pennsylvania, which serves as...
- The Defense Logistics Agency awarded a delivery order valued at $3,708.36 to AmerisourceBergen Drug Corp for Kerendia 10 mg tablets (30-count packages) on June 18, 2025, with completion targeted for June 20, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and is being fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Kerendia 10 mg tablets (30-count packages) with a ceiling value of $1,529.00. This is a firm fixed-price delivery order with no set-aside designation, representing a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026....
- The Defense Logistics Agency awarded a $5,589.39 delivery order to AmerisourceBergen Drug Corp for KERENDIA 10 mg tablets (90 count) with a completion date of July 18, 2025. This contract was competitively awarded with no set-aside designation and utilizes firm fixed price terms. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $5,185.78 to AmerisourceBergen Drug Corp for the supply of Kerendia 20 mg tablets (30-count) on October 16, 2025, with an ultimate completion date of October 17, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,430.52 for Kerendia 10 mg tablets (90-count packaging) on July 15, 2025, with an ultimate completion date of July 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $5,008.41 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Kerendia 10 mg, a medication used in the treatment of chronic kidney disease. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure with an ultimate completion date of September 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $8,335.49 to AmerisourceBergen Drug Corp for Kerendia 20 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The contract is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Kerendia 10 mg tablets in a quantity of 30 units. This is a firm fixed-price delivery order with a ceiling value of $4,760.59 and an ultimate completion date of September 4, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Kerendia is a brand-name pharmaceutical...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB26FP4NQDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,430.89 to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Kerendia 10 mg tablets (90-count). The contract, which is competitively awarded with no set-aside designation, carries a firm fixed price and is scheduled for completion by October 24, 2025. AmerisourceBergen Drug Corp will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, maintains a substantial portfolio of federal medical procurement contracts with the DLA and Defense Health Agency. The company supplies a comprehensive range of pharmaceutical products and medical commodities across multiple therapeutic domains, including brand-name and generic medications, vaccines, and specialized medical devices. Kerendia is indicated for treating chronic kidney disease and cardiovascular complications in patients with diabetes, supporting military and veteran healthcare needs through the DLA's extensive medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 10/23/25 |